Antiarrhythmic Endpoint Of Reduced VT/VF And Death Supported By Cmte.
Executive Summary
Clinical trials of antiarrhythmic drugs should use a composite endpoint of reduced mortality and the number of "appropriate" shocks from implanted cardioverter-defibrillators, FDA's Cardio-Renal Drugs Advisory Committee suggested April 30.